Pieter J. van Runnard Heimel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pieter J. van Runnard Heimel has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Arie Franx
Department of Perinatology and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands
2 shared publicationsHein W. Bruinse
Department of Perinatology and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands
2 shared publicationsA F.A.M. Schobben
1 shared publicationA Franx
1 shared publicationA J.M. Huisjes
1 shared publicationA. Franx
1 shared publication
Latest Publications
- 1 January 2008
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 27 (3) , 253-265
HELLP Syndrome Is Associated with an Increased Inflammatory Response, Which May Be Inhibited by Administration of Prednisolone
To investigate the effect of prednisolone on HELLP syndrome by assessing several markers of the inflammatory response and hepatic damage associated with HELLP syndrome. Prospective study. Single-center, tertiary obstetric care facility at the University Medical Centre Utrecht, The Netherlands. Study subjects included normal controls, patients with non-HELLP preeclampsia, and patients with preeclampsia and HELLP syndrome. HELLP syndrome was defined by hemolysis (serum lactate dehydrogenase [LDH] >600 IU/L and/or haptoglobin 70 U/L and/or serum alanine aminotransferase [ALT] >70 U/L), and a low platelet count (<100 x 10(9)/L). Blood samples from patients with HELLP syndrome who were receiving either prednisolone or placebo were obtained before, during, and after a HELLP exacerbation in the antepartum period. Plasma levels of CRP, IL-1RA, IL-6, sIL-6R, IL-8, IL-10, TNF-alpha, and GSTA1-1 were determined. Samples from women with preeclampsia but without HELLP syndrome and from healthy pregnant women were included as controls. Plasma levels of CRP, IL-1RA, IL-6, sIL-6R, IL-8, IL-10, TNF-alpha, and GSTA1-1. During a HELLP exacerbation CRP, IL-6, IL-1Ra, and GSTA1-1 levels are significantly increased (p < 0.01). In the group of patients treated with prednisolone, significantly lower IL-6 levels were observed during a HELLP exacerbation, compared with patients who did not receive prednisolone (p < 0.01). HELLP syndrome is associated with an increased inflammatory response. Circulating IL-6 levels in HELLP syndrome are reduced during prednisolone administration, suggesting a stabilizing effect on the inflammatory endothelial process.
- 1 January 2008
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 27 (3) , 253-265
HELLP Syndrome Is Associated with an Increased Inflammatory Response, Which May Be Inhibited by Administration of Prednisolone
To investigate the effect of prednisolone on HELLP syndrome by assessing several markers of the inflammatory response and hepatic damage associated with HELLP syndrome. Prospective study. Single-center, tertiary obstetric care facility at the University Medical Centre Utrecht, The Netherlands. Study subjects included normal controls, patients with non-HELLP preeclampsia, and patients with preeclampsia and HELLP syndrome. HELLP syndrome was defined by hemolysis (serum lactate dehydrogenase [LDH] >600 IU/L and/or haptoglobin 70 U/L and/or serum alanine aminotransferase [ALT] >70 U/L), and a low platelet count (<100 x 10(9)/L). Blood samples from patients with HELLP syndrome who were receiving either prednisolone or placebo were obtained before, during, and after a HELLP exacerbation in the antepartum period. Plasma levels of CRP, IL-1RA, IL-6, sIL-6R, IL-8, IL-10, TNF-alpha, and GSTA1-1 were determined. Samples from women with preeclampsia but without HELLP syndrome and from healthy pregnant women were included as controls. Plasma levels of CRP, IL-1RA, IL-6, sIL-6R, IL-8, IL-10, TNF-alpha, and GSTA1-1. During a HELLP exacerbation CRP, IL-6, IL-1Ra, and GSTA1-1 levels are significantly increased (p < 0.01). In the group of patients treated with prednisolone, significantly lower IL-6 levels were observed during a HELLP exacerbation, compared with patients who did not receive prednisolone (p < 0.01). HELLP syndrome is associated with an increased inflammatory response. Circulating IL-6 levels in HELLP syndrome are reduced during prednisolone administration, suggesting a stabilizing effect on the inflammatory endothelial process.
- 1 September 2006
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 128 (1-2) , 187-193
A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term
- 1 September 2006
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 128 (1-2) , 187-193
A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term
- 1 January 2005
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 60 (1) , 57-70
Corticosteroids, Pregnancy, and HELLP Syndrome: A Review
Corticosteroids are potent antiinflammatory and immunosuppressive drugs, which are used in the treatment of a wide range of medical disorders. During pregnancy, several corticosteroids are administered for maternal as well as fetal reasons. Prednisone and prednisolone show limited transplacental passage and are thus used for treatment of maternal disease. Dexamethasone and betamethasone, drugs that can easily cross the placenta, are more suitable for fetal indications. During the last decade, administration of corticosteroids was introduced in the treatment of hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), a severe form of preeclampsia unique to human pregnancy. Several randomized, controlled trials as well as other prospective and retrospective studies have been performed to investigate this beneficial effect of corticosteroids on biochemical measures and clinical signs. This review discusses the characteristics of corticosteroids in humans and details the use of corticosteroids during pregnancy. A review of literature on the effect of corticosteroids on HELLP syndrome is given and possible mechanisms of action are discussed. Obstetricians & Gynecologists, Family Physicians After completion of this article, the reader should be able to compare the relative strength of the commercially available steroids, to outline the pharmacologic characteristics of glucocorticoids in humans, to compare the anti-inflammatory characteristics of corticosteroids, to explain the changes in glucocorticoid metabolism during pregnancy, and to list the effects of corticosteroids on the fetus.
- 1 January 2005
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 60 (1) , 57-70
Corticosteroids, Pregnancy, and HELLP Syndrome: A Review
Corticosteroids are potent antiinflammatory and immunosuppressive drugs, which are used in the treatment of a wide range of medical disorders. During pregnancy, several corticosteroids are administered for maternal as well as fetal reasons. Prednisone and prednisolone show limited transplacental passage and are thus used for treatment of maternal disease. Dexamethasone and betamethasone, drugs that can easily cross the placenta, are more suitable for fetal indications. During the last decade, administration of corticosteroids was introduced in the treatment of hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), a severe form of preeclampsia unique to human pregnancy. Several randomized, controlled trials as well as other prospective and retrospective studies have been performed to investigate this beneficial effect of corticosteroids on biochemical measures and clinical signs. This review discusses the characteristics of corticosteroids in humans and details the use of corticosteroids during pregnancy. A review of literature on the effect of corticosteroids on HELLP syndrome is given and possible mechanisms of action are discussed. Obstetricians & Gynecologists, Family Physicians After completion of this article, the reader should be able to compare the relative strength of the commercially available steroids, to outline the pharmacologic characteristics of glucocorticoids in humans, to compare the anti-inflammatory characteristics of corticosteroids, to explain the changes in glucocorticoid metabolism during pregnancy, and to list the effects of corticosteroids on the fetus.